Provided by Tiger Fintech (Singapore) Pte. Ltd.

INmune Bio Inc

2.69
-0.1650-5.78%
Post-market: 2.65-0.0399-1.48%19:59 EDT
Volume:1.49M
Turnover:3.95M
Market Cap:71.51M
PE:-1.39
High:2.74
Open:2.73
Low:2.54
Close:2.86
Loading ...

BRIEF-Xpro™ Reduces Amyloid And Enhances Behavior Post

Reuters
·
11 Jun

INmune Bio Inc. Announces Promising Results from XPro™ Clinical Study, Showing Reduction in Alzheimer's-like Pathology Post-TBI

Reuters
·
11 Jun

INmune Bio Inc. to Present at RBC Capital Markets Global Healthcare Conference in 2025

Reuters
·
14 May

INmune Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
10 May

INmune Bio Q1 EPS $(0.43) Beats $(0.47) Estimate, Sales $50.00K Up From $14.00K YoY

Benzinga
·
09 May

INmune Bio Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
05 May

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

GlobeNewswire
·
16 Apr

INmune Bio partners with Cell, Gene Therapy Catapult to scale up CORDStrom

TIPRANKS
·
14 Apr

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

GlobeNewswire
·
14 Apr

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

GlobeNewswire
·
01 Apr

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com
·
28 Mar

INmune Bio Q4 EPS $(0.40) Beats $(0.53) Estimate

Benzinga
·
28 Mar

Press Release: INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Dow Jones
·
28 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

INmune Bio Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
25 Mar

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

GlobeNewswire
·
24 Mar

Inmune Bio (INMB) Receives a Buy from Scotiabank

TIPRANKS
·
05 Mar

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Simply Wall St.
·
27 Feb

INmune Bio Is Maintained at Buy by Maxim Group

Dow Jones
·
14 Feb

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

GlobeNewswire
·
12 Feb